J&J jumps on the RNA bandwagon, inking discovery deal with Remix for a potentially new class of drugs
Among the hottest fields in drug discovery, RNA therapeutics have taken the world of Big Pharma by storm. J&J, not normally the tip of the spear on emerging science, is now joining its peers in taking out a bet on the future of RNA — this time with a Boston-area biotech targeting the pre-translation process.
J&J will pay $45 million in upfront cash and downstream milestones for up to three candidates from Remix Therapeutics, a biotech working on small molecule drugs to alter RNA processing before protein translation, the partners said Thursday. In all, the deal could be worth more than $1 billion, the companies said.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.